H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Celcuity to $185 from $165 and keeps a Buy rating on the shares. With the announcement of Study 2 of VIKTORIA-2, the firm included revenues from front-line endocrine-resistant and endocrine-sensitive populations in its revenue model.
